MFDS — authorised 6 April 2011
- Marketing authorisation holder: IPR PHARMS INC
- Status: likely_approved
🇰🇷 Caprelsa in South Korea
MFDS authorised Caprelsa on 6 April 2011
Marketing authorisation
Caprelsa in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in South Korea
Frequently asked questions
Is Caprelsa approved in South Korea?
Yes. MFDS authorised it on 6 April 2011.
Who is the marketing authorisation holder for Caprelsa in South Korea?
IPR PHARMS INC holds the South Korean marketing authorisation.